Biocon has been imposed a penalty of Rs 3.04 crore over GST-related issues. The company has received an order of adjudication imposing a penalty dated February 22, 2024, from the office of Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalore.
The demand is related to input tax credit reporting error in GST monthly returns, denial of input tax credit on sales and promotional expenditures, valuation issue GST under corporate guarantee, and denial of exemption on export of services. The company is in the process of taking appropriate actions, including but not limited to, filing of the necessary appeal with the appellate authority in this regard. There is no material impact on the financials, operations or other activities of the company.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1673.15 |
| Dr. Reddys Lab | 1236.65 |
| Cipla | 1236.45 |
| Zydus Lifesciences | 938.75 |
| Lupin | 2328.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: